Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.57 |
| ▸ | PPARG | P37231 | 8/20 | 0.57 |
| ▸ | PPARD | Q03181 | 8/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | FBP1 | P09467 | 4/20 | 0.36 |
| ▸ | PDE2A | O00408 | 5/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16243352 | 0.91 | PPARA (0.64) | PPARAPPARGPPARDABCB11CYP1A2 | |
| SCHEMBL16243168 | 0.90 | PPARA (0.48) | PPARAPPARGPPARDABCB11CYP1A2 | |
| SCHEMBL16242791 | 0.89 | PPARA (0.56) | PPARAPPARGPPARDABCB11CYP1A2 | |
| SCHEMBL15068185 | 0.89 | PPARA (0.69) | PPARAPPARGPPARDTSHR | |
| SCHEMBL16243217 | 0.88 | PPARA (0.56) | PPARAPPARGPPARDABCB11CYP1A2 | |
| SCHEMBL16242925 | 0.84 | PPARA (0.80) | PPARAPPARGPPARDABCB11CYP1A2 | |
| SCHEMBL16242927 | 0.84 | PPARA (0.68) | PPARAPPARGPPARDABCB11CYP1A2 | |
| SCHEMBL15066869 | 0.81 | PPARA (0.54) | PPARAPPARGPPARDABCB11CYP1A2 | |
| SCHEMBL15067893 | 0.81 | PPARA (0.79) | PPARAPPARGPPARDTSHR | |
| SCHEMBL16243274 | 0.79 | PPARA (0.47) | PPARAPPARGPPARDABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115073-B2 | 1,3-diphenylpropane derivatives, preparations and uses thereof | GENFIT (FR) | 2015-08-25 | — | — | US | disclosed |
| US-20140350112-A1 | 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES THEREOF | GENFIT (FR) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350112-A1 | 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES THEREOF | PPARD, PPARA, PPARG | PPARA 2/4885PPARG 3/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.